1767-63-1

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 114570-69-3 3-(2-furyl)-1-(4-methoxyphenyl)propen-1-one 
• 1366233-07-9 C₂₄H₂₅NO₄ 
• 1188265-06-6 7-(4-methoxyphenyl)-4,7-dioxoheptanoic acid ethyl ester 
• 98-01-1 furfural 

Relevant academic research and scientific papers

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: Carboxamide modification

The enzyme S-nitrosoglutathione reductase (GSNOR) is a member of the alcohol dehydrogenase family (ADH) that regulates the levels of S-nitrosothiols (SNOs) through catabolism of S-nitrosoglutathione (GSNO). GSNO and SNOs are implicated in the pathogenesis of many diseases including those in respiratory, gastrointestinal, and cardiovascular systems. The pyrrole based N6022 was recently identified as a potent, selective, reversible, and efficacious GSNOR inhibitor which is currently in clinical development for acute asthma. We describe here the synthesis and structure-activity relationships (SAR) of novel pyrrole based analogs of N6022 focusing on carboxamide modifications on the pendant N-phenyl moiety. We have identified potent and novel GSNOR inhibitors that demonstrate efficacy in an ovalbumin (OVA) induced asthma model in mice.